VASADE BIOSCIENCES, INC.

Barnegat Light, NJ · Biotech · Private

AC5 inhibitor small molecule (C90) for reducing myocardial infarction damage post-reperfusion

Grants
$2.5M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction$172,153
Federal grantDepartment of Health and Human Services · Phase II · Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction$1,388,427
Federal grantDepartment of Health and Human Services · Phase II · Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction$715,042
Federal grantDepartment of Health and Human Services · Phase I · A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease$252,130
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2989ROCKETML, INC.——
2990ATHGHIN BIOTECHNOLOGY, INC.——
2991Twentyeight-Seven Therapeutics——
2992VASADE BIOSCIENCES, INC.——
2993Pharvaris——
2994TRIMTECH——
2995NeuroCycle Therapeutics, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Adenyl Cyclase Inhibitors, Pharmaceutical Compositions and Methods of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.